Conference report: Positive data from pooled post-hoc subgroup analysis of phase III studies (BIPARK-1 and 2) of opicapone as add on therapy in patients with Parkinson's disease

Data showed opicapone decreased "off" time vs placebo (109.2 vs. 40.3 mins; p=0.0161) and increased "on" time vs. entacapone (124 vs. 60 mins; p=0.0344), as an add-on therapy to levodopa/carbidopa in patients with Parkinson's disease who experience motor fluctuations.

Biospace Inc.